Dermatomyositis, Interstitial Pneumonitis, Polymyositis
Conditions
Keywords
Interstitial pneumonitis, Polymyositis, Dermatomyositis, Tacrolimus, Corticosteroids
Brief summary
The purpose of the study is to evaluate the efficacy and safety of the combination treatment of tacrolimus and corticosteroid in polymyositis/dermatomyositis patients with interstitial pneumonitis with comparison against corticosteroid-treated historical controls.
Detailed description
Interstitial pneumonia (IP) is a common complication of and has a significant impact on the prognosis of patients with polymyositis (PM) and dermatomyositis (DM). Reported prevalence of IP in PM/DM patients varies between 23 to 65% depending on criteria applied as well as on clinical settings of studied cohorts, and an earlier overview and a later study reported its high short-term mortality. However, treatment for this grave complication has not yet been either established or even been prospectively investigated. Glucocorticoids, while long been considered as the first-line drugs, is effective in less than 50% of patients. Furthermore, the mortality of these glucocorticoids-resistant patients does not improve even if immunosuppressive drugs are later added. Recently, we and others reported retrospective data which suggest that either an early addition of immunosuppressive drugs to glucocorticoids or the combined use of glucocorticoids and immunosuppressive drugs from the initial treatment may improve the survival of PM/DM patients. To save lives of PM/DM-IP patients, desperate treating physicians have started using this approach, strongly urging the conduct of prospective studies to investigate the superiority of this approach over glucocorticoids alone. At the same time, it was considered not ethically appropriate to conduct a prospective study with a concurrent controlled group receiving glucocorticoids alone given the presence of the PM/DM-IP subtype with rapidly progressive course and high short-term mortality if treated with glucocorticoids alone and the absence of useful demographic or bio-markers which could distinguish patients with this subtype early. Among immunosuppressive drugs used in the treatment of PM/DM-IP, tacrolimus has recently been suggested to be effective even for those patients who are resistant to cyclosporine or cyclosphosphamide. To investigate whether the combined initial treatment of glucocorticoids and tacrolimus is superior to glucocorticoids alone in PM/DM-IP patients, we conducted a multicenter clinical trial to evaluate the efficacy and safety of a combination treatment of glucocorticoids and tacrolimus for 1 year in patients with newly developed active PM/DM-IP or its relapse by comparing against clinical outcome of historical control patients who were treated with glucocorticoid alone as an initial treatment.
Interventions
DRUGTacrolimus
Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
Sponsors
Japan Medical Association
Astellas Pharma Inc
Tokyo Medical and Dental University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
Experimental treatment group 1. Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed by Sontheimer et al 2. High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a radiologist. If consolidation is the only abnormal findings, the patient must have pathologically documented evidence of interstitial pneumonitis of other histological type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia (the patient could have more than one histological type including cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia) 3. Meet two or more of the following criteria (must include 1) 1. Serum KL-6 above the upper normal limit 2. Presence of dyspnea on exertion (grade 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index 3. PaO2 of less than 80 mmHg while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2 4. Vital capacity \< 80% predicted, or diffusing capacity for carbon monoxide \< 65% predicted 5. Meet at least one of the following condition over the 12-week period (84 days) prior to the initiation of the study drug * Decrease in either % forced vital capacity or % diffusing capacity for carbon monoxide of 10% or more * Worsening of interstitial pneumonitis findings by chest CT, confirmed by a radiologist 4. 16 to 74 years of age Historical control group 1. Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed by Sontheimer et al 2. High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a radiologist. If consolidation is the only abnormal findings, the patient must have pathologically documented evidence of interstitial pneumonitis of other histological type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia (the patient could have more than one histological type including cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia) 3. Meet two or more of the following criteria (must include 1) 1. Serum KL-6 above the upper normal limit 2. Presence of dyspnea on exertion (grade 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index 3. PaO2 of less than 80 mmHg while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2 4. Vital capacity \< 80% predicted, or diffusing capacity for carbon monoxide \< 65% predicted 5. Meet at least one of the following condition over the 12-week period (84 days) prior to the initiation of the study drug * Decrease in either % forced vital capacity or % diffusing capacity for carbon monoxide of 10% or more * Worsening of interstitial pneumonitis findings by chest CT, confirmed by a radiologist 4. Use of corticosteroids at doses equivalent to between 0.6 to 1.0mg/kg/day of prednisolone for 14 days or longer to treat interstitial pneumonitis on or after the day when the inclusion criteria (3) was met (up to two courses of pulse IV corticosteroid therapy within the first 28 days are allowed) 5. 16 to 74 years of age
Exclusion criteria
Experimental treatment group 1. Use of corticosteroids at doses equivalent to or higher than prednisolone 0.6mg/kg/day within 4 weeks (28 days) prior to the initiation of the study drug 2. Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days) prior to the initiation of the study drug 3. Could not exclude the following conditions on clinical ground: drug-induced pneumonitis, occupational lung disease, hypersensitivity pneumonitis, radiation-induced lung injury 4. Presence of end-stage interstitial pneumonitis as identified on the basis of a vital capacity \< 45% predicted, diffusing capacity for carbon monoxide \< 30% predicted, or lung CT with predominantly honeycombing appearance 5. Presence of pancreatitis 6. Presence of diabetes mellitus with the exception of glucocorticoid-induced one that is well-controlled (HbA1c \< 6.5%) 7. Serum creatinine of 1.5 mg/dL or above 8. Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper limit of normal) with the exception of the one that is considered to be due to myositis and is accompanied by the elevation of muscle enzymes above the upper limit of normal 9. Serum potassium above the upper limit of normal 10. Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart failure, or pulmonary hypertension requiring treatment 11. Presence or history of malignancy with the exception of those without relapse off treatment for 5 years or longer 12. Presence of serious active infection 13. Presence of active hepatitis B, hepatitis C, or HIV infection 14. History of severe drug hypersensitivity reaction 15. Patients who are pregnant or breast-feeding, or patients who intend to or whose spouses intend to conceive during the course of the study, including the follow-up period 16. Participation in another clinical trial or post-marketing clinical study within 26 weeks (182 days) prior to screening 17. Other medical condition which, in the investigator's judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes Historical control group 1. Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days) prior to or 2 weeks (14 days) after the corticosteroid treatment as defined by the inclusion criteria (4) is initiated 2. Could not exclude the following conditions on clinical ground: drug-induced pneumonitis, occupational lung disease, hypersensitivity pneumonitis, radiation-induced lung injury 3. Presence of end-stage interstitial pneumonitis as identified on the basis of a vital capacity \< 45% predicted, diffusing capacity for carbon monoxide \< 30% predicted, or lung CT with predominantly honeycombing appearance 4. Presence of pancreatitis 5. Presence of diabetes mellitus with the exception of glucocorticoid-induced one that is well-controlled (HbA1c \< 6.5%) 6. Serum creatinine of 1.5 mg/dL or above 7. Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper limit of normal) with the exception of the one that is considered to be due to myositis and is accompanied by the elevation of muscle enzymes above the upper limit of normal 8. Serum potassium above the upper limit of normal 9. Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart failure, or pulmonary hypertension requiring treatment 10. Presence or history of malignancy with the exception of those without relapse off treatment for 5 years or longer 11. Presence of serious active infection including active hepatitis B, hepatitis C, or HIV infection 12. Other medical condition which, in the investigator's judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 52 weeks | Overall survival (OS) was calculated from the day on which the protocol treatment was started until death due to any cause. Participants still alive were censored at the date they were last known to be alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | 52 weeks | Patients were considered to have reached the progression if they died, or if they met all the following criteria; (1) ≥10% decline from baseline FVC or ≥15mmHg increase in baseline resting P(A-a)O2, (2) a worsening of interstitial pneumonitis findings by chest CT compared to the most recent study, confirmed by a radiologist, and (3) exclusion of pneumocystis pneumonia, cytomegalovirus pneumonia, and other pulmonary infection on clinical ground. |
Countries
Japan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Prospective Investigation Group Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
Tacrolimus: Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg. | 25 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | Lack of Efficacy | 4 |
| Overall Study | Physician Decision | 1 |
Baseline characteristics
| Characteristic | Prospective Investigation Group |
|---|---|
| Age, Continuous | 55.4 years STANDARD_DEVIATION 12 |
| Sex: Female, Male Female | 19 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 25 |
| other Total, other adverse events | 25 / 25 |
| serious Total, serious adverse events | 11 / 25 |
Outcome results
Primary
Overall Survival
Overall survival (OS) was calculated from the day on which the protocol treatment was started until death due to any cause. Participants still alive were censored at the date they were last known to be alive.
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Prospective Investigation Group | Overall Survival | 88.0 percentage of participants |
Secondary
Progression-free Survival
Patients were considered to have reached the progression if they died, or if they met all the following criteria; (1) ≥10% decline from baseline FVC or ≥15mmHg increase in baseline resting P(A-a)O2, (2) a worsening of interstitial pneumonitis findings by chest CT compared to the most recent study, confirmed by a radiologist, and (3) exclusion of pneumocystis pneumonia, cytomegalovirus pneumonia, and other pulmonary infection on clinical ground.
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Prospective Investigation Group | Progression-free Survival | 76.4 percentage of participants |